Silveira, Douglas R. A., Coelho-Silva, Juan L., Silva, Wellington F., Vallance, Grant, Pereira-Martins, Diego A., Madeira, Maria I. A., Figueredo-Pontes, Lorena L., Velloso, Elvira D. R. P., Simões, Belinda P., Peniket, Andy, Danby, Robert, Rego, Eduardo M., Vyas, Paresh, Traina, Fabiola, Bendit, Israel, Quek, Lynn, and Rocha, Vanderson
Outcomes in acute myeloid leukemia (AML) are dependent on patient- and disease-characteristics, treatment, and socioeconomic factors. AML outcomes between resource-constrained and developed countries have not been compared directly. We analyzed two cohorts: from São Paulo state, Brazil (USP, n = 312) and Oxford, United Kingdom (OUH, n = 158). USP cohort had inferior 5-year overall survival compared with OUH (29% vs. 49%, adjusted-p=.027). USP patients have higher early-mortality (23% vs. 6% p<.001) primarily due to multi-resistant Gram-negative bacterial and fungal infections. USP had higher 5-year cumulative incidence of relapse (60% vs. 50%, p=.0022), were less likely to undergo hematopoietic stem cell transplant (HSCT) (28% vs. 75%, p<.001) and waited longer for HSCT (median, 23.8 vs. 7.2 months, p<.001). Three-year survival in relapsed patients was worse in USP than OUH (10% vs. 39%, p<.001). Our study indicates that efforts to improve AML outcomes in Brazil should focus on infection prevention and control, and access to HSCT. [ABSTRACT FROM AUTHOR]